IRIS Accounts Production v24.2.0.383 11463856 director 1.9.22 31.12.23 31.12.23 19.9.24 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh114638562022-08-31114638562023-12-31114638562022-09-012023-12-31114638562021-12-31114638562022-01-012022-08-31114638562022-08-3111463856ns15:EnglandWales2022-09-012023-12-3111463856ns14:PoundSterling2022-09-012023-12-3111463856ns10:Director12022-09-012023-12-3111463856ns10:PrivateLimitedCompanyLtd2022-09-012023-12-3111463856ns10:SmallEntities2022-09-012023-12-3111463856ns10:Audited2022-09-012023-12-3111463856ns10:SmallCompaniesRegimeForDirectorsReport2022-09-012023-12-3111463856ns10:SmallCompaniesRegimeForAccounts2022-09-012023-12-3111463856ns10:FullAccounts2022-09-012023-12-3111463856ns10:CompanySecretary12022-09-012023-12-3111463856ns10:RegisteredOffice2022-09-012023-12-3111463856ns5:CurrentFinancialInstruments2023-12-3111463856ns5:CurrentFinancialInstruments2022-08-3111463856ns5:Non-currentFinancialInstruments2023-12-3111463856ns5:Non-currentFinancialInstruments2022-08-3111463856ns5:ShareCapital2023-12-3111463856ns5:ShareCapital2022-08-3111463856ns5:SharePremium2023-12-3111463856ns5:SharePremium2022-08-3111463856ns5:RetainedEarningsAccumulatedLosses2023-12-3111463856ns5:RetainedEarningsAccumulatedLosses2022-08-3111463856ns5:ComputerEquipment2022-09-012023-12-3111463856ns5:ComputerEquipment2022-08-3111463856ns5:ComputerEquipment2023-12-3111463856ns5:ComputerEquipment2022-08-3111463856ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3111463856ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-08-311146385612022-09-012023-12-31
REGISTERED NUMBER: 11463856 (England and Wales)















FINANCIAL STATEMENTS

FOR THE PERIOD 1 SEPTEMBER 2022 TO 31 DECEMBER 2023

FOR

PANDEIA THERAPEUTICS LIMITED

PANDEIA THERAPEUTICS LIMITED (REGISTERED NUMBER: 11463856)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Period 1 September 2022 to 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


PANDEIA THERAPEUTICS LIMITED

COMPANY INFORMATION
for the Period 1 September 2022 to 31 December 2023







DIRECTOR: Mrs J Rhodes





SECRETARY: The Cambridge Partnership Limited





REGISTERED OFFICE: C/o The Cambridge Partnership Ltd
The Dorothy Hodgkin Building
Babraham Research Campus, Babraham
Cambridge
Cambridgeshire
CB22 3FH





REGISTERED NUMBER: 11463856 (England and Wales)





AUDITORS: HBB Audit Limited
Bridge House
25 Fiddlebridge Lane
Hatfield
Hertfordshire
AL10 0SP

PANDEIA THERAPEUTICS LIMITED (REGISTERED NUMBER: 11463856)

BALANCE SHEET
31 December 2023

31.12.23 31.8.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 343 957

CURRENT ASSETS
Debtors 5 258,204 280,123
Cash at bank 178,617 796,269
436,821 1,076,392
CREDITORS
Amounts falling due within one year 6 161,786 247,747
NET CURRENT ASSETS 275,035 828,645
TOTAL ASSETS LESS CURRENT
LIABILITIES

275,378

829,602

CREDITORS
Amounts falling due after more than one
year

7

1,570,800

-
NET (LIABILITIES)/ASSETS (1,295,422 ) 829,602

CAPITAL AND RESERVES
Called up share capital 5,062 5,062
Share premium 4,090,905 4,090,905
Retained earnings (5,391,389 ) (3,266,365 )
SHAREHOLDERS' FUNDS (1,295,422 ) 829,602

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 18 September 2024 and were signed by:





Mrs J Rhodes - Director


PANDEIA THERAPEUTICS LIMITED (REGISTERED NUMBER: 11463856)

NOTES TO THE FINANCIAL STATEMENTS
for the Period 1 September 2022 to 31 December 2023

1. STATUTORY INFORMATION

Pandeia Therapeutics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 20% on cost

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

PANDEIA THERAPEUTICS LIMITED (REGISTERED NUMBER: 11463856)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Period 1 September 2022 to 31 December 2023

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
As at 31 December 2023, the company has negative reserves and is dependent upon the continued support of its parent company. The accounts have been prepared on a going concern basis in the knowledge this support will continue.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 (2022 - 3 ) .

4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 September 2022
and 31 December 2023 2,298
DEPRECIATION
At 1 September 2022 1,341
Charge for period 614
At 31 December 2023 1,955
NET BOOK VALUE
At 31 December 2023 343
At 31 August 2022 957

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.8.22
£    £   
Trade debtors - 1,525
Other debtors 258,204 278,598
258,204 280,123

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.8.22
£    £   
Trade creditors 66,946 241,446
Other creditors 94,840 6,301
161,786 247,747

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.12.23 31.8.22
£    £   
Amounts owed to group undertakings 1,570,800 -

PANDEIA THERAPEUTICS LIMITED (REGISTERED NUMBER: 11463856)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Period 1 September 2022 to 31 December 2023

8. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Paul Skipper BSc FCA (Senior Statutory Auditor)
for and on behalf of HBB Audit Limited

9. ULTIMATE CONTROLLING PARTY

The company is a wholly owned subsidiary of Acadia Pharmaceuticals Inc, an incorporated company registered
in the State of Delaware, United States of America, which owns 100% of the called up share capital.

As at 31 December 2023 the ultimate parent undertaking and controlling party is Acadia Pharmaceuticals Inc.

The results of Pandeia Therapeutics Limited are included in the consolidated financial statements of Acadia Pharmaceuticals Inc. , which are available from its registered office at 12830 El Camino Real, Ste. 400, San Diego, CA 92130, USA .